Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
Conditions
- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage III Pancreatic Cancer
- Stage IV Pancreatic Cancer
Interventions
- BIOLOGICAL: ipilimumab
- DRUG: gemcitabine hydrochloride
- OTHER: laboratory biomarker analysis
Sponsor
Northwestern University
Collaborators